After identifying anatomical risk factors for OSA, such as small upper airways, dentists can then refer at-risk patients to sleep medicine specialists for diagnostic testing, according to the report.

Something went wrong. ProSomnus EVO devices are being used exclusively for the precision OAT arm of the study. 136 patients with moderate and severe OSA were included in the study.

FLOSAT is an ongoing prospective, independent, head-to-head, crossover study comparing the effectiveness of precision OAT as first-line treatment versus CPAP therapy. ProSomnus EVO™ devices are ...

Precision oral appliance therapy effective among 90% of moderate and 85% of severe OSA patients In an Intent-to-Treat analysis, precision OAT demonstrated twice the mean disease alleviation as ...

PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (OSA), announced the presentation of ...

89% of all patients and 98.5% of mild to moderate OSA patients were treated to an apnea-hypopnea index (AHI) of fewer than ten events per hour. 80% of severe OSA patients were treated to an AHI of ...

Since 2015, the American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine (AADSM) have recommended that sleep physicians consider OAT for mild to moderate sleep apnea ...

"ProSomnus Precision OAT devices help increase patient compliance and safety for Veterans living with Obstructive Sleep Apnea (OSA). I think it’s safe to say, no one enjoys sleeping with a CPAP.

This investigation is one of the first to demonstrate the efficacy of precision OAT, or any OSA treatment for that matter, using a risk-based (sleep apnea specific hypoxic burden “SASHB”) index.

This investigation is one of the first to demonstrate the efficacy of precision OAT, or any OSA treatment for that matter, using a risk-based (sleep apnea specific hypoxic burden “SASHB”) index.